The Drug-Induced Respiratory Disease Website and App

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.ap Cytokine release syndrome - Cytokine storm

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.ap Cytokine release syndrome - Cytokine storm

I. Interstitial/parenchymal lung disease

I.ap Pulmonary infiltrates

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.a Pulmonary edema, noncardiogenic (NCPE)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.c Interstitial pulmonary edema

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.p Acute respiratory or cardiopulmonary failure

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.c Hemoptysis

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLVI. Pulmonary vasculopathy

XLVI.a Pulmonary embolism - Venous thrombosis/thromboembolism

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.ap Cytokine release syndrome - Cytokine storm

LI. Cardiovascular involvement / toxicity

LI.a Left or biventricular dysfunction/failure

LI. Cardiovascular involvement / toxicity

LI.c Pericardial effusion (w/wo tamponade)

LI. Cardiovascular involvement / toxicity

LI.g Cardiomyopathy (acute, subacute, chronic)

LI. Cardiovascular involvement / toxicity

LI.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

LI. Cardiovascular involvement / toxicity

LI.o Cardiovascular collapse - Cardiogenic shock - Hypotension

LI. Cardiovascular involvement / toxicity

LI.q QTc prolongation

LI. Cardiovascular involvement / toxicity

LI.s Heart failure (biventricular, congestive)

LI. Cardiovascular involvement / toxicity

LI.u Cardiac- cardiorespiratory/pulmonary arrest

LI. Cardiovascular involvement / toxicity

LI.ah Coronary vasospasm - Vasospastic angina

LI. Cardiovascular involvement / toxicity

LI.aj Tachycardia

LI. Cardiovascular involvement / toxicity

LI.ak Cardiotoxicity

LI. Cardiovascular involvement / toxicity

LI.bd Sudden cardiac death

LI. Cardiovascular involvement / toxicity

LI.bv ST segment elevation

LI. Cardiovascular involvement / toxicity

LI.bw ST segment changes

LIX. Infections & related conditions

LIX.b Opportunistic pulmonary/systemic infections

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.ap Cytokine release syndrome - Cytokine storm

LI. Cardiovascular involvement / toxicity

LI.d Myocarditis (can be fulminant)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.a Pulmonary edema, noncardiogenic (NCPE)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLIII. Airway involvement

XLIII.a Bronchospasm - Wheezing - Asthma

XLIII. Airway involvement

XLIII.ab Cough (lone)

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.a Angioedema (may cause UAO, asphyxia and death)

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.h Laryngospasm (a.k.a. laryngismus)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.ap Cytokine release syndrome - Cytokine storm

LI. Cardiovascular involvement / toxicity

LI.ah Coronary vasospasm - Vasospastic angina

LVIII. Pathology

LVIII.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

LVIII. Pathology

LVIII.f Path: ILD with a granulomatous component (see also Im)

LVIII. Pathology

LVIII.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.n ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.p Focal/localized area of pneumonitis/fibrosis

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

I. Interstitial/parenchymal lung disease

I.ae Radiation recall pneumonitis

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.h Major/massive hemoptysis

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.l Alveolar hemorrhage, localized (e.g. lobar)

XLIII. Airway involvement

XLIII.a Bronchospasm - Wheezing - Asthma

XLIII. Airway involvement

XLIII.c Exacerbation or deterioration of preexisting asthma

XLIII. Airway involvement

XLIII.d Exacerbation or deterioration of preexisting COPD

XLIII. Airway involvement

XLIII.j Bronchiectasis

XLIII. Airway involvement

XLIII.l Large airway inflammation - Tracheitis (w/wo tissue eosinophilia)

XLIII. Airway involvement

XLIII.t Eosinophilic airway disease (asthma, bronchitis, bronchiolitis)

XLIII. Airway involvement

XLIII.u Sptutum production - Bronchorrhea - 'Bronchitis'

XLIII. Airway involvement

XLIII.w Bronchiolitis (a clinical-imaging pattern suggestive of)

XLIII. Airway involvement

XLIII.x Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

XLIII. Airway involvement

XLIII.ab Cough (lone)

XLIII. Airway involvement

XLIII.af Sputum production - Bonchorrhea - ‘Bronchitis’

XLIII. Airway involvement

XLIII.ag Obstructive airway dysfunction (see also IVc, XVx)

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.g Vocal cord paresis/paralysis

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.r Tongue involvement (edema, glossitis, hematoma)

XLV. Pleural and/or pericardial involvement

XLV.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

XLVI. Pulmonary vasculopathy

XLVI.a Pulmonary embolism - Venous thrombosis/thromboembolism

XLVI. Pulmonary vasculopathy

XLVI.b Pulmonary arterial hypertension

XLVII. Mediastinal involvement

XLVII.a Lymphadenopathy (intrathoracic)

XLVII. Mediastinal involvement

XLVII.e Granulomatous mediastinal lymphadenopathy

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.r Myasthenia gravis - Myasthenic-like syndrome

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.b Antiphospholipid antibodies w/wo the APL syndrome

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.c Capillary leak syndrome (CLS)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.d Lupus - Lupus syndrome (see also Vd)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.l Myopathy-Myositis-Polymyositis (see also under Xba)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.m Sarcoid-like granulomatosis (endo-/extrathoracic)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.aj Granulomatosis with polyangiitis (typically ANCA pos.) - GPA flare

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.ap Cytokine release syndrome - Cytokine storm

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.ax Connective tissue disease

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.ay Scleroderma

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.az Polymyalgia rheumatica

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.bj Temporal arteritis (Horton’s)

L. Miscellaneous

L.e Metabolic acidosis (incl. lactic acidosis/-gap). May cause hyperpnea/dyspnea

L. Miscellaneous

L.l Neutropenia, agranulocytosis (w/wo infection/sepsis)

LI. Cardiovascular involvement / toxicity

LI.a Left or biventricular dysfunction/failure

LI. Cardiovascular involvement / toxicity

LI.c Pericardial effusion (w/wo tamponade)

LI. Cardiovascular involvement / toxicity

LI.d Myocarditis (can be fulminant)

LI. Cardiovascular involvement / toxicity

LI.s Heart failure (biventricular, congestive)

LI. Cardiovascular involvement / toxicity

LI.t Heart block (bundle branch- or AV-)

LV. Imaging

LV.b Imaging: Ground-glass opacities (GGO) / shadowing

LV. Imaging

LV.e Imaging: Pulmonary opacities with a subpleural distribution

LV. Imaging

LV.k Imaging: An area or areas of consolidation

LV. Imaging

LV.v Imaging: Centrilobular micronodules (can be diffuse)

LV. Imaging

LV.aa Imaging: A large nodule or a mass

LV. Imaging

LV.ak Imaging: A 'tree-in-bud' pattern

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.a BAL: An excess proportion of lymphocytes

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.b BAL: An excess proportion of neutrophils

LVIII. Pathology

LVIII.a Path: NSIP-cellular pattern (see also Ia, Ib)

LVIII. Pathology

LVIII.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

LVIII. Pathology

LVIII.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

LVIII. Pathology

LVIII.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

LVIII. Pathology

LVIII.f Path: ILD with a granulomatous component (see also Im)

LVIII. Pathology

LVIII.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

LVIII. Pathology

LVIII.al Path: Acute/subacute bronchiolitis (see also IVc, IVi)

LVIII. Pathology

LVIII.au Path: Airway inflammation

LVIII. Pathology

LVIII.co Path: Myocarditis

LVIII. Pathology

LVIII.cr Path: Myocardial vasculitis

LIX. Infections & related conditions

LIX.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

LIX. Infections & related conditions

LIX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

LIX. Infections & related conditions

LIX.o Nocardia pulmonary/systemic infection

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.p Tumor lysis syndrome (TLS)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.ap Cytokine release syndrome - Cytokine storm